Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer

By Hubert Ayala   Mali Bela   Hamburger Tamar   Rottenberg Yakir   Uziely Beatrice   Peretz Tamar   Kadouri Luna  

Familial Cancer, Vol. 8, Iss. 3, 2009-09 ,pp. : 173-177

Springer Publishing Company

Access to resources Recommend Favorite

(Neo-)adjuvant chemotherapy in breast cancer - Trials, errors and new rationales from the SABCS 2007

By Dubsky P.  

memo - Magazine of European Medical Oncology, Vol. 1, Iss. 1, 2008-03 ,pp. : 23-26

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer - the role of clinical response

By Pierga J.-Y.   Mouret E.   Laurence V.   Dieras V.   Savigioni A.   Beuzeboc P.   Dorval T.   Palangie T.   Jouve M.   Pouillart P.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1089-1096

Elsevier

Access to resources Recommend Favorite

High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer

By Abrial Sophie   Penault-Llorca Frédérique   Delva Rémi   Bougnoux Philippe   Leduc Bernard   Mouret-Reynier Marie-Ange   Mery-Mignard Dominique   Bleuse Jean-Pierre   Dauplat Jacques   Curé Hervé   Chollet Philippe  

Breast Cancer Research and Treatment, Vol. 94, Iss. 3, 2005-12 ,pp. : 255-263

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer

By                

Oncology Letters, Vol. 4, Iss. 4, 2012-01 ,pp. : 612-616

Spandidos Publications

Access to resources Recommend Favorite